3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Oxaliplatin
42
Fluorouracil
27
Capecitabine
24
pembrolizumab
21
S 1 (combination)
19
Paclitaxel
19
Leucovorin
16
Nivolumab
13
Docetaxel
13
sintilimab
12
Drug Therapy
12
Trastuzumab
11
tislelizumab
10
Cisplatin
10
Irinotecan
9
Bevacizumab
8
trastuzumab deruxtecan
7
spartalizumab
7
XELOX
7
Surgical Procedures, Operative
7
Radiotherapy
7
Hyperthermic Intraperitoneal Chemotherapy
7
Biopsy
7
fludarabine
6
disitamab vedotin
6
Cyclophosphamide
6
lenvatinib
5
apatinib
5
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Stomach Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled